"Double Pound" breakthrough clinical research results released, providing new options for diabetes treatment

2021 On 8 Yue 24- th, 81 th American Diabetes Society ( ADA ) Annual Conference on 6 came to an end at the end, many areas of clinical diabetes research project at the meeting announced the latest progress and achievements
.

Taking this opportunity, since July , Sanofi has held the 2021 BEYOND-ADA advanced academic seminar (hereinafter referred to as the " seminar " ) in more than ten cities across the country , inviting many experts and clinicians in the field of diabetes to participate in diabetes.
Global research advances such as clinical treatment and hypoglycemia prevention were shared and discussed .
At the same time, through vivid videos , the professional knowledge is interpreted and shared with the majority of professional doctors .

2021 On 8 Yue 24- th, 81 th American Diabetes Society ( Diabetes ADA ) Annual Conference on 6 came to an end at the end, a number of clinical research projects in the field of diabetes at the meeting announced the latest progress and achievements

SoliMix : a new option for patients using premixed insulin SoliMix : a new option for patients using premixed insulin

Premixed insulin is widely applied in China, more than about half of China 2 using premixed insulin when insulin-treated patients with type ⁱ , although premixed insulin is considered to be a more common treatment options, there is still in its clinical application Obvious risk of hypoglycemia and weight gain ^issuesii
.

Premixed insulin is widely applied in China, more than about half of China 2 using premixed insulin when insulin-treated patients with type ^{i i} , although premixed insulin is considered to be a more common treatment options, it is still in clinical application There are obvious risks of hypoglycemia and weight gain ^{ii ii}
.

The seminar shared and discussed the first head-to-head study of basal insulin and GLP-1RA compound preparation ( iGlarLixi* ) and premixed insulin announced at the ADA conference - SoliMix .
The results of the SoliMix study show that iGlarLixi is more effective than premixed insulin and significantly reduces body weight .
Meanwhile, iGlarLixi also has better control of fasting blood glucose, insulin dose less, less risk of hypoglycemia advantages ^III .
In addition, the burden of treatment, daily life, diabetes manage multiple dimensions, patient compliance, such as mental health and treatment, iGlarLixi patient-reported outcomes are better than premixed insulin ^iv .

The seminar shared and discussed the first head-to-head study of basal insulin and GLP-1RA compound preparation ( iGlarLixi* ) and premixed insulin announced at the ADA conference - SoliMix .

The results of the SoliMix study show that iGlarLixi is more effective than premixed insulin and significantly reduces body weight .
At the same time, iGlarLixi also has the advantages of better fasting blood glucose control, fewer insulin doses, and lower risk of hypoglycemia ^{iii iii} .
In addition, in terms of treatment burden, daily life, diabetes management , patient compliance, mental health, and treatment effect, patients who manage iGlarLixi report better outcomes than premixed insulin ^{iv iv} .

Professor Yang Wenying from the Endocrinology Department of the China-Japan Friendship Hospital said in an interview: "After the ADA meeting, we will still be able to keep abreast of the most advanced international developments in the development of innovative drugs in the new epidemic era, such as the SoliMix research

BEYOND V : Exploring the choice of insulin treatment plan after short-term hospitalization BEYOND V : Exploring the choice of insulin treatment plan after short-term hospitalization

According to statistics, China has nearly 50 percent of diabetes patients starting insulin therapy during hospitalization ^v , these patients hospitalized mainly due to high blood sugar, the primary goal of treatment is to control high blood sugar, improve the high glucose toxicity
.

At present, short-term inpatient intensive insulin therapy is the main treatment method for these patients, but how to choose an appropriate treatment plan after discharge from the hospital is still a clinical problem to be solved

According to statistics, China has nearly 50 percent of diabetes patients starting insulin therapy during hospitalization ^{v v} , these patients hospitalized mainly due to high blood sugar, the primary goal of treatment is to control high blood sugar, improve the high glucose toxicity

In this context, director of the Beijing Hospital of Endocrinology Professor and Professor Yoshiaki mother Guo Lixin, director of the PLA General Hospital, Department of Endocrinology led efforts BEYOND V study, poor oral hypoglycemic agents control and received short-term intensive insulin therapy 2 diabetes In patients, the efficacy and safety of insulin glargine U100 combined with oral hypoglycemic drugs and twice a day premixed insulin (biphasic insulin aspart 30 , BIAsp30 ) combined with oral hypoglycemic drugs were compared

Professor Guo Lixin, director of Beijing Hospital, Department of Endocrinology, said in an interview: " After the short-term intensive insulin therapy, Chinese 2 diabetic patients long-term maintenance program has many choices, and the BEYOND V provide patients with intensive insulin therapy in the choice of insulin regimen study The

Dr.

* * iGlarLixi iGlarLixi is an injectable hypoglycemic drug, which is composed of insulin glargine 100U/mL 100U/mL and

References   References  

ⁱ Polinski JM, et al.

^{i i} Polinski JM, et al.

^{ii ii} Meece J Diabetes Ther 2018;9:877–90

ⁱⁱⁱ Rosenstock, Julio et al.
Diabetes Care.
2021 Jun 28; dc210393.

^{iii iii} Rosenstock, Julio et al.
Diabetes Care.
2021 Jun 28; dc210393.

^iv 2021 ADA ePoster 747 P-Improved Treatment Perceptions with iGlarLixi vs Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient-reported Outcomes (PROs) of the SoliMix Trial

^{iv iv} 2021 ADA ePoster 747 P-Improved Treatment Perceptions with iGlarLixi vs Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient-reported Outcomes (PROs) of the SoliMix Trial

^v Liu, Jing, et al.
Advances in therapy 37.
4 (2020): 1675-1687.

^{v v} Liu, Jing, et al.
Advances in therapy 37.
4 (2020): 1675-1687.
Leave a message here